Inner ear cell therapy targeting hereditary deafness by activation of stem cell homing factors

Kazusaku Kamiya*
Department of Otorhinolaryngology, Faculty of Medicine, Juntendo University, Tokyo, Japan

Edited by:
Hiroshi Hibino, Niigata University, Japan

Reviewed by:
Yumi Ohta, Osaka University, Japan
Genki Ogata, Niigata University, Japan

*Correspondence:
Kazusaku Kamiya, Department of Otorhinolaryngology, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
e-mail: kkamiya@juntendo.ac.jp

Congenital deafness affects about 1 in 1000 children and more than half of them have a genetic background such as Connexin26 (CX26) gene mutation. Inner ear cell therapy for sensorineural hearing loss has been expected to be an effective therapy for hereditary deafness. Previously, we developed a novel strategy for inner ear cell therapy using bone marrow mesenchymal stem cells as a supplement for cochlear fibrocytes functioning for cochlear ion transport. For cell therapy targeting hereditary deafness, a more effective cell delivery system to induce the stem cells into cochlear tissue is required, because gene mutations affect all cochlear cells cochlear cells expressing genes such as GJB2 encoding CX26. Stem cell homing is one of the crucial mechanisms to be activated for efficient cell delivery to the cochlear tissue. In our study, monocyte chemotactic protein-1, stromal cell-derived factor-1 and their receptors were found to be a key regulator for stem cell recruitment to the cochlear tissue. Thus, the activation of stem cell homing may be an efficient strategy for hearing recovery in hereditary deafness.

Keywords: hereditary deafness, stem cell homing, mesenchymal stem cell, inner ear cell therapy, connexin26

HEREDITARY DEAFNESS AND THE MOUSE MODELS ASSOCIATED WITH IONIC HOMEOSTASIS IN COCHLEA

Approximately one in 1,000 children is affected by severe hearing loss at birth or during early childhood, which is defined as pre-lingual deafness (Morton, 1991; Petersen and Willems, 2006) with about half of the cases attributable to genetic causes (Birkenhager et al., 2010). Among >100 known forms of non-syndromic deafness with identified genetic loci, by far the most common and best characterized is the one associated with GJB2 (OMIM 121011), the gene encoding the connexin26 (CX26) protein (Kelsell et al., 1997). Recently we demonstrated that a mutation in CX26 induces macromolecular degradation of large gap junction plaque (GJP) complexes by using a CX26 dominant negative transgenic (Inoshita et al., 2014) and deficient mouse model (Kamiya et al., 2014). This molecular pathogenesis called “GJP disruption” is thought to be associated with a decreased endocochlear potential (EP) generated by cochlear ion transport. GJP disruption was also found in a mouse model for deafness type 3 (DFN3), which is the most common type of in X chromosome–linked, non-syndromic hearing loss. This mouse model has a deficiency of transcription factor Brn4 encoded by POU domain, class 3, transcription factor 4 (POU3F4; Kidokoro et al., 2014). We reported that the low EP observed in this mouse appeared to be caused by GJP disruption. A mouse model with a mutation in BSND, which encodes barttin, shows Bartter syndrome type IV, a hearing impairment (Nomura et al., 2013) also thought to be caused by a low EP.

INNER EAR CELL THERAPY TARGETING COCHLEAR FIBROCYTE

Previously, we demonstrated that local inflammation at the lateral wall promotes the invasion of transplanted mesenchymal stem cells (MSCs) to the lateral wall (Kamiya et al., 2007). In our microarray analysis with cochlear mRNA after 3-nitropropionic acid (3-NP) administration, we showed the up-regulation of chemokine MCP-1 (monocyte chemotactic protein-1) which is known to be a stem cell homing factor (Belema-Bedada et al., 2008). Thus, the invasion of MSCs shown in our previous study was thought to be enhanced by stem cell homing factors.

STEM CELL HOMING

Stem cell homing is one the crucial mechanisms to be activated for efficient cell delivery to the cochlear tissue. Belema-Bedada et al. (2008) demonstrated that efficient homing of multipotent adult MSCs into hearts damaged by ischemia/reperfusion was dependent on FRONT-Mediated clustering of chemokine (C-C motif) receptor 2 (CCR2). They showed that the cytokine receptor CCR2 is necessary for organ-specific homing of pluripotent adult MSCs and that these cells are recruited by the CCR2 ligand MCP-1/CCL2 and express stromal cell-derived factor 1 (SDF-1), which might trap additional bone marrow-derived circulating cells to contribute to the complex process of homing and retention of circulating stem and progenitor cells to remodel diseased organs. As for homing to cochlea, Tan et al. (2008) demonstrated the homing capability of bone marrow-derived cells to a deafened cochlea. They suggested that the upregulation of SDF-1 in the
spiral ligament after acoustic deafening promoted homing of the cell to the cochlea (Tan et al., 2008).

**ACTIVATION OF STEM CELL HOMING FACTORS IN COCHLEA AND STEM CELLS**

To establish an efficient cell therapy for hereditary deafness, we examined treatments that enhanced stem cell homing factors in the cochlear tissue and MSC. We examined inner ear MSC transplantation in CX26 deficient mice, which we developed as a model of hereditary hearing loss (Kamiya et al., 2014). We transplanted the MSCs to the lateral semicircular canal after the induction of stem cell homing factors (SDF-1; MCP-1) in the host cochlear tissue, and their receptors in transplanted MSCs. To enhance the invasion by MSCs of the cochlear tissue, we developed a novel transplant strategy by inducing SDF-1/MCP-1 expression in the host cochlear tissue and enhanced the expression of their receptors, CCR2 and C-X-C chemokine receptor type 4 (CXCR4) in MSCs (Figure 1). With this strategy, we induced efficient invasion of MSCs to the inner ear tissue and differentiation to form gap junctions with CX26 among transplanted MSCs in CX26-deficient mouse inner ear (unpublished observation).

By using newly generated mouse models and a new strategy for the activation of stem cell homing factors, it may be possible to establish an efficient inner ear cell therapy for recovering hearing in hereditary deafness.

**ACKNOWLEDGMENTS**

This work was supported in part by a research grant from the Ministry of Education, Science and Culture, MEXT-support program for the Strategic Research Foundation at Private Universities, 2011–2014 and Takeda Science Foundation.

**REFERENCES**

Belema-Bedada, F., Uchida, S., Martire, A., Kostin, S., and Braun, T. (2008). Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2. *Cell Stem Cell* 2, 566–575. doi: 10.1016/j.stem.2008.03.003

Birkenhager, R., Lublinghoff, N., Prera, E., Schild, C., Aschendorff, A., and Arndt, S. (2010). Autosomal dominant prelingual hearing loss with palmoplantar...
Kamiya Inner ear cell therapy

keratoderma syndrome: variability in clinical expression from mutations of R75W and R75Q in the GJB2 gene. *Am. J. Med. Genet. A* 152A, 1798–1802. doi: 10.1002/ajmg.a.33464

Inoshita, A., Karasawa, K., Funakubo, M., Miwa, A., Ikeda, K., and Kamiya, K. (2014). Dominant negative connexin26 mutation R75W causing severe hearing loss influences normal programmed cell death in postnatal organ of Corti. *BMC Genet.* 15:1. doi: 10.1186/1471-2156-15-1

Kamiya, K., Fujinami, Y., Hoya, N., Okamoto, Y., Kouike, H., Komatsuzaki, R., et al. (2007). Mesenchymal stem cell transplantation accelerates hearing recovery through the repair of injured cochlear fibrocytes. *Am. J. Pathol.* 171, 214–226. doi: 10.2353/ajpath.2007.060948

Kamiya, K., Yum, S. W., Kurebayashi, N., Muraki, M., Ogawa, K., Karasawa, K., et al. (2014). Assembly of the cochlear gap junction macromolecular complex requires connexin 26. *J. Clin. Invest.* 124, 1598–1607. doi: 10.1172/JCI67621

Kelsell, D. P., Dunlop, J., Stevens, H. P., Lench, N. J., Liang, J. N., Parry, G., et al. (1997). Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. *Nature* 387, 80–83. doi: 10.1038/387080a0

Kidokoro, Y., Karasawa, K., Minowa, O., Sugitani, Y., Noda, T., Ikeda, K., et al. (2014). Deficiency of transcription factor Brn4 disrupts cochlear gap junction plaques in a model of DFN3 non-syndromic deafness. *PLoS ONE* 9:e108216. doi: 10.1371/journal.pone.0108216

Morton, N. E. (1991). Genetic epidemiology of hearing impairment. *Ann. N. Y. Acad. Sci.* 630, 16–31. doi: 10.1111/j.1749-6632.1991.tb19572.x

Nomura, N., Kamiya, K., Ikeda, K., Yui, N., Chiga, M., Sohara, E., et al. (2013). Treatment with 17-allylamino-17-demethoxygeldanamycin ameliorated symptoms of Bartter syndrome type IV caused by mutated Bsnd in mice. *Biochim. Biophys. Res. Commun.* 441, 544–549. doi: 10.1016/j.bbrc.2013.10.129

Petersen, M. B., and Willems, P. J. (2006). Non-syndromic, autosomal-recessive deafness. *Clin. Genet.* 69, 371–392. doi: 10.1111/j.1399-0004.2006.00613.x

Tan, B. T., Lee, M. M., and Ruan, R. (2008). Bone-marrow-derived cells that home to acoustic deafened cochlea preserved their hematopoietic identity. *J. Comp. Neurol.* 509, 167–179. doi: 10.1002/cne.21729

**Conflict of Interest Statement:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 10 December 2014; accepted: 06 January 2015; published online: 27 January 2015.

Citation: Kamiya K (2015) Inner ear cell therapy targeting hereditary deafness by activation of stem cell homing factors. *Front. Pharmacol.* 6:2. doi: 10.3389/fphar.2015.00002

This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology. Copyright © 2015 Kamiya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

www.frontiersin.org January 2015 | Volume 6 | Article 2 | 3